Case Reports
Vol. 4 No. 1 (2012): Reviews, Articles, Case Reports and Letters
Methotrexate induced lung injury in a patient with primary CNS lymphoma: A case report
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: April 2, 2012
6221
Views
1158
Downloads
5042
HTML
hematology,
lymphomas,
pharmacology of anticancer drugs
Authors
Methotrexate is an antimetabolite commonly used in clinical practice for a variety of indications ranging from rheumatoid arthritis and other connective tissue disorders to high dose regimens in many malignancies. This folate antagonist has got a spectrum of toxicities among which gastrointestinal effects predominate . Lung injury is a well described but rare event and has been reported most often in patients who have been on long term oral therapy for rheumatic disorders. Acute lung injury in a patient receiving a high dose regimen for haematological malignancies has not been reported previously. We present one such case of methotrexate related acute lung injury in a patient of primary CNS lymphoma receiving high dose methotrexate.
Downloads
Download data is not yet available.
Citations
Ethics Approval
case reportHow to Cite
“Methotrexate induced lung injury in a patient with primary CNS lymphoma: A case report” (2012) Mediterranean Journal of Hematology and Infectious Diseases, 4(1), p. e2012020. doi:10.4084/mjhid.2012.020.
